Shares of micro-cap company Biomerica Inc. (BMRA) gained 30% on Tuesday morning after the biomedical technology company said its new Covid-19 antigen test received CE mark.
BMRA is currently trading at $6.79, up $1.65 or 32.06%, on the Nasdaq.
Biomerica said it has received CE Mark for its new COVID-19 Rapid Antigen Test for detection of COVID-19 infection. The company has already received its first European orders and plans to ship the first part of these orders in the coming weeks.
For comments and feedback contact: editorial@rttnews.com